Evidence map›Paper›PMID 29163703›Full record

ArticleOncology letters2017

The downregulation of c-Myc and its target gene hTERT is associated with the antiproliferative effects of baicalin on HL-60 cells.

Xia Ren, Zhiyong Zhang, Jing Tian, Hengxiao Wang, Guanhua Song, Qiang Guo, Jing Tian, Yang Han, Qiong Liao, Guoqiang Liu and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Advances in Anti-Cancer Activities of Flavonoids inInternational journal of molecular sciences · 2022
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Xia RenKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Zhiyong ZhangKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Jing TianLaboratory Department, People's Hospital of Zhangqiu, Zhangqiu, Shandong 250200, P.R. China.
Hengxiao WangKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Guanhua SongKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Qiang GuoKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Jing TianKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Yang HanKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Qiong LiaoKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Guoqiang LiuDepartment of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China.
Huifang DingDepartment of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China.
Guosheng JiangKey Laboratory for Rare and Uncommon Diseases of Shandong and Key Laboratory for Tumor Immunology and Chinese Medicine Immunology of Shandong, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China.
Shandong First Medical University · CNShengli Oilfield Central Hospital · CNZhangqiu City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Baicalin is a flavonoid compound isolated from Scutellaria baicalensis, a Chinese traditional medicinal herb, and is used as an anti-inflammatory, antibacterial, anxiolytic and hepatoprotective drug. Accumulating evidence has demonstrated that baicalin exhibits potent antitumor properties by suppressing cell growth, arresting cell cycle progression and inducing differentiation or apoptosis in leukemia cell lines. However, whether or not the extrinsic pathway is involved in baicalin-induced apoptosis of leukemia cells and the mechanisms underlying the antitumor activity of baicalin remain unclear. In the present study, the effect of baicalin on the expression of caspase-8, Fas cell surface death receptor (Fas) and Fas ligand in HL-60 cells was assessed, and it was demonstrated that the Fas-mediated extrinsic pathway was also involved in baicalin-triggered cell apoptosis, in addition to the intrinsic pathway. Furthermore, baicalin was able to inhibit the proliferation of HL-60 cells by arresting the cell cycle at the G

Indexed as

apoptosisbaicalincaspasesextrinsic pathwayHL-60 cellshuman telomerase reverse transcriptaseMyc proto-oncogene proteinproliferation

Identifiers

PMID29163703
PMCPMC5688794
OpenAlexW2757109611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.